Barr Pharmaceuticals.

Tri – Norinyl annual sales of approximately $ 20 million for the twelve months to the end of July 2004, IMS data.Barr Pharmaceuticals, a holding company that operates through its principal subsidiaries, Barr Laboratories and Duramed Pharmaceuticals, is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals.

This information was of with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at– Situational ethics involved in in the handling containing classified info the national security and client privileges.